Medication info
J-Gaba Capsule 75 mg (Pregabalin)

J-Gaba Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Hard capsule with a brownish upper and white lower part containing white powder
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 202000752 · Approved 2020.02.10 · Insurance code 645406510

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this drug is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (Refer to ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to ‘4. Discontinuation of Administration’) 2. Epilepsy Adults: This drug may be administered at a starting dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, administration of doses exceeding 450 mg/day is not recommended. 4. Discontinuation of Administration Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys in unchanged form. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *For women, multiply the result obtained using the above formula by 0.85. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Administration is not recommended in children under 12 years of age and adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in epilepsy patients, whether or not there are secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. These effects play a crucial role in the management of neurological and pain-related conditions.

How to take

Adult dose

This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this drug is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (Refer to ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to ‘4. Discontinuation of Administration’) 2. Epilepsy Adults: This drug may be administered at a starting dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, administration of doses exceeding 450 mg/day is not recommended. 4. Discontinuation of Administration Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys in unchanged form. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *For women, multiply the result obtained using the above formula by 0.85. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Administration is not recommended in children under 12 years of age and adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if mood changes or unusual behaviors occur during treatment, you should consult a healthcare professional immediately. Patients allergic to any components of this medication or those with certain hereditary lactose metabolism disorders should not take it. Diabetic patients may experience weight gain after taking this medication, which may require adjustments in their blood sugar control medications. If allergic reactions such as angioedema occur, the medication should be stopped immediately and healthcare professionals informed. Elderly patients may experience increased dizziness or drowsiness when taking this medication, so caution is needed, and safety measures should be taken if symptoms occur. Temporary blurring of vision or changes in vision may occur; if abnormal symptoms appear, patients should inform a healthcare professional. Discontinuing the medication may result in withdrawal symptoms such as insomnia, headache, or anxiety, so dosage should be adjusted in consultation with a healthcare professional. Taking this medication with other drugs that affect the central nervous system may exacerbate side effects, so it is crucial to inform healthcare professionals about any other medications being taken. Patients with decreased kidney function may require dose adjustments. During early pregnancy, there is a risk of fetal malformation, so women who are pregnant or planning to become pregnant must consult a physician before taking this medication and ensure effective contraception. In breastfeeding, this medication can pass into breast milk; thus, it is vital to discuss with healthcare professionals whether to discontinue breastfeeding or the medication. Driving or operating dangerous machinery should be avoided until dizziness or drowsiness resolves after taking this medication. Overdosing may result in confusion, drowsiness, seizures, etc., and immediate emergency treatment is necessary. It should be stored in a safe place out of reach of children and should not be transferred to another container. If serious adverse reactions such as skin rash, fever, or difficulty breathing occur while taking this medication, it should be halted immediately and healthcare professionals informed.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 192 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • reduced libido
  • depersonalization
  • sexual hypersensitivity
  • agitation
  • mood swings
  • emotional lability
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulse control difficulties
  • flat affect
  • ataxia
  • impaired coordination
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • decreased sensation
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • fasciculations
  • diminished reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • diplopia
  • dry eyes
  • eye swelling
  • reduced vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibrations
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • abdominal distension
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory changes
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • mood disorders
  • drowsiness
  • confusion.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent contact with air or moisture, and it is advisable to store it at room temperature between 15 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

Hard capsule with a brownish upper and white lower part containing white powder

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.